Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510528 | 0.89 | MAPT (0.39) | L3MBTL1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4518576 | 0.86 | SMN1; SMN2 (0.38) | L3MBTL1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4514869 | 0.76 | RAB9A (0.40) | L3MBTL1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4038685 | 0.75 | CRHR1 (0.37) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL4038688 | 0.74 | CRHR1 (0.39) | GABRA2GABRB2 | |
| SCHEMBL3114685 | 0.73 | CRHR1 (0.38) | L3MBTL1SMN1; SMN2MAPTCNR1GABRA2 | |
| SCHEMBL3102348 | 0.72 | DPP4 (0.41) | — | |
| SCHEMBL6666901 | 0.70 | L3MBTL1 (0.74) | L3MBTL1RAB9APOLBMAPTMEN1 | |
| SCHEMBL3109826 | 0.70 | GRM5 (0.38) | MAPTCNR1HPGDALDH1A1 | |
| SCHEMBL755285 | 0.68 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | TPMT, QDPR, HNMT | L3MBTL1 4820/4885NPC1 3884/4885RAB9A 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.